Insider · CIK 0001585697
Lawrence J. Hineline
Files at ITCI (Intra-Cellular Therapies, Inc.). First filing Feb 5, 2024, latest Mar 11, 2024.
In brief
Lawrence J. Hineline files SEC Form 4 as CFO at ITCI (Intra-Cellular Therapies, Inc.). Since Feb 5, 2024, Lawrence J. Hineline has reported 0 open-market buys worth $0 and 3 open-market sells worth $3.2M, the latest filed on Mar 11, 2024.
A track record needs three past buys with six months of prices behind them; Lawrence J. Hineline has 0, so none is measured yet.
The newest scored trade: sold $1.5M of ITCI on Mar 7, 2024, filed Mar 11, 2024, scored 47 (moderate), under a 10b5-1 plan.
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 47Moderate | Intra-Cellular Therapies, Inc. | $1.5M 23,253 shares | -177% | - | |
| 46Moderate | Intra-Cellular Therapies, Inc. | $926k 13,337 shares | -179% | - | |
| 58Moderate | Intra-Cellular Therapies, Inc. | $745k 11,183 shares | -100% | - |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Mar 11, 2024 | ITCI Intra-Cellular Therapies, Inc. | 10,121 0.01% of outstanding | $668k | Mar 11, 2024 | $2.5M |
| Mar 7, 2024 | ITCI Intra-Cellular Therapies, Inc. | 13,132 0.01% of outstanding | $875k | Mar 7, 2024 | $1.7M |
| Feb 26, 2024 | ITCI Intra-Cellular Therapies, Inc. | 13,337 0.01% of outstanding | $926k | Feb 26, 2024 | $745k |
| Feb 2, 2024 | ITCI Intra-Cellular Therapies, Inc. | 11,183 0.01% of outstanding | $745k | Feb 2, 2024 | none |
Transactions
Every row this insider has filed, 26 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Mar 7, 2024 | ITCI Intra-Cellular Therapies, Inc. | SOpen-market sale Common Stock10b5-1 | -6,514 | $66.26 | $432k | 6,618 | Mar 11, 2024 |
| Mar 7, 2024 | ITCI Intra-Cellular Therapies, Inc. | SOpen-market sale Common Stock10b5-1 | -6,618 | $66.93 | $443k | 0 | Mar 11, 2024 |
| Mar 10, 2024 | ITCI Intra-Cellular Therapies, Inc. | MOption exercise Common Stock10b5-1 | +5,582 | - | - | 5,582 | Mar 11, 2024 |
| Mar 11, 2024 | ITCI Intra-Cellular Therapies, Inc. | SOpen-market sale Common Stock10b5-1 | -4,453 | $65.28 | $291k | 1,129 | Mar 11, 2024 |
| Mar 11, 2024 | ITCI Intra-Cellular Therapies, Inc. | SOpen-market sale Common Stock10b5-1 | -1,100 | $66.54 | $73k | 29 | Mar 11, 2024 |
| Mar 11, 2024 | ITCI Intra-Cellular Therapies, Inc. | SOpen-market sale Common Stock10b5-1 | -29 | $67.32 | $1,952 | 0 | Mar 11, 2024 |
| Mar 10, 2024 | ITCI Intra-Cellular Therapies, Inc. | MOption exercise Common Stock10b5-1 | +4,539 | $56.73 | $257k | 4,539 | Mar 11, 2024 |
| Mar 11, 2024 | ITCI Intra-Cellular Therapies, Inc. | SOpen-market sale Common Stock10b5-1 | -4,475 | $66.47 | $297k | 64 | Mar 11, 2024 |
| Mar 11, 2024 | ITCI Intra-Cellular Therapies, Inc. | SOpen-market sale Common Stock10b5-1 | -64 | $67.12 | $4,296 | 0 | Mar 11, 2024 |
| Mar 10, 2024 | ITCI Intra-Cellular Therapies, Inc. | MOption exercise Restricted Stock Unitsderivative10b5-1 | -5,582 | $0.00 | $0 | 5,582 | Mar 11, 2024 |
| Mar 10, 2024 | ITCI Intra-Cellular Therapies, Inc. | MOption exercise Stock Option (right to purchase)derivative10b5-1 | -4,539 | $0.00 | $0 | 4,539 | Mar 11, 2024 |
| Mar 6, 2024 | ITCI Intra-Cellular Therapies, Inc. | MOption exercise Common Stock | +13,132 | - | - | 13,132 | Mar 8, 2024 |
| Mar 6, 2024 | ITCI Intra-Cellular Therapies, Inc. | MOption exercise Restricted Stock Unitsderivative | -13,132 | $0.00 | $0 | 26,266 | Mar 8, 2024 |
| Mar 1, 2024 | ITCI Intra-Cellular Therapies, Inc. | AGrant or award Restricted Stock Unitsderivative | +26,227 | $0.00 | $0 | 26,227 | Mar 5, 2024 |
| Feb 23, 2024 | ITCI Intra-Cellular Therapies, Inc. | MOption exercise Common Stock10b5-1 | +7,455 | - | - | 7,455 | Feb 27, 2024 |
| Feb 26, 2024 | ITCI Intra-Cellular Therapies, Inc. | SOpen-market sale Common Stock10b5-1 | -300 | $68.33 | $20k | 7,155 | Feb 27, 2024 |
| Feb 26, 2024 | ITCI Intra-Cellular Therapies, Inc. | SOpen-market sale Common Stock10b5-1 | -6,867 | $69.38 | $476k | 288 | Feb 27, 2024 |
| Feb 26, 2024 | ITCI Intra-Cellular Therapies, Inc. | SOpen-market sale Common Stock10b5-1 | -288 | $70.15 | $20k | 0 | Feb 27, 2024 |
| Feb 26, 2024 | ITCI Intra-Cellular Therapies, Inc. | MOption exercise Common Stock10b5-1 | +5,882 | $36.89 | $217k | 5,882 | Feb 27, 2024 |
| Feb 26, 2024 | ITCI Intra-Cellular Therapies, Inc. | SOpen-market sale Common Stock10b5-1 | -5,282 | $69.47 | $367k | 600 | Feb 27, 2024 |
| Feb 26, 2024 | ITCI Intra-Cellular Therapies, Inc. | SOpen-market sale Common Stock10b5-1 | -600 | $69.81 | $42k | 0 | Feb 27, 2024 |
| Feb 23, 2024 | ITCI Intra-Cellular Therapies, Inc. | MOption exercise Restricted Stock Unitsderivative10b5-1 | -7,455 | $0.00 | $0 | 0 | Feb 27, 2024 |
| Feb 26, 2024 | ITCI Intra-Cellular Therapies, Inc. | MOption exercise Stock Option (right to buy)derivative10b5-1 | -5,882 | $0.00 | $0 | 0 | Feb 27, 2024 |
| Feb 1, 2024 | ITCI Intra-Cellular Therapies, Inc. | AGrant or award Common Stock10b5-1 | +11,183 | $0.00 | $0 | 11,183 | Feb 5, 2024 |
| Feb 2, 2024 | ITCI Intra-Cellular Therapies, Inc. | SOpen-market sale Common Stock10b5-1 | -10,998 | $66.61 | $733k | 185 | Feb 5, 2024 |
| Feb 2, 2024 | ITCI Intra-Cellular Therapies, Inc. | SOpen-market sale Common Stock10b5-1 | -185 | $67.35 | $12k | 0 | Feb 5, 2024 |
Questions about Lawrence J. Hineline
Answered from the filings on this page, as of the latest one.
Is Lawrence J. Hineline buying or selling?
Not in the last 12 months. Lawrence J. Hineline's latest open-market trade on SEC Form 4 was sold $1.5M of ITCI on Mar 7, 2024.
How did Lawrence J. Hineline's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Lawrence J. Hineline has 0.
Where does Lawrence J. Hineline file Form 4?
Lawrence J. Hineline has filed Form 4 at ITCI (Intra-Cellular Therapies, Inc.) as SVP of Finance, CFO. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.